Skip to content

Timing of Resistance Exercise in Type 1 Diabetes

Timing of Resistance Exercise, Glucose Control and Exercise Adaptations in People With Type 1 Diabetes: a Randomised-controlled Trial

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05884814
Acronym
T-REX
Enrollment
54
Registered
2023-06-01
Start date
2023-07-01
Completion date
2024-12-31
Last updated
2023-07-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 1 Diabetes

Keywords

exercise, circadian rhythm, glucose control, muscle, strength

Brief summary

The aims of the current study are 1. to compare the effects of acute morning and afternoon resistance exercise on blood glucose levels in people with type 1 diabetes. 2. to compare the effects of morning and afternoon resistance exercise training on cardiometabolic health outcomes in people with type 1 diabetes

Interventions

Between 6-10am participants will attend the gym and perform 10 min of warm up exercise, 3 sets of 7 resistance exercises ( leg press, calf press, leg curl, chest press, lateral raise, seated row and plank)

Between 4-8pm participants will attend the gym and perform 10 min of warm up exercise, 3 sets of 7 resistance exercises ( leg press, calf press, leg curl, chest press, lateral raise, seated row and plank)

BEHAVIORALHabitual physical activity levels

Participants will be asked to maintain their normal activity levels

Sponsors

Dasman Diabetes Institute
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

1:1:1 parallel group design

Eligibility

Sex/Gender
ALL
Age
21 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

* Physician confirmed type 1 diabetes for at least 1 year * Stable insulin therapy for 3 months prior to the study

Exclusion criteria

* BMI of 45 or higher * BP of 160/100mmHg or higher * autonomic neuropathy * severe proliferative retinopathy * joint or limb injuries preventing weight-bearing activity * autonomic neuropathy * severe proliferative retinopathy * any other medical condition that prevents participants from exercising safely.

Design outcomes

Primary

MeasureTime frameDescription
Change in muscle strengthChange from baseline to 12 weeksSum of one repetition maximum for the 7 resistance exercise
Change in interstitial glucose time in rangeChange from 6 hours before (baseline) to 6 hours after (post-exercise) an exercise training sessionInterstitial glucose time in range (3.9-10mmol/L) measured via continuous glucose monitoring

Secondary

MeasureTime frameDescription
Change in physical functionChange from baseline to 12 weeksMeasured by the short performance physical battery
Change in HbA1cChange from baseline to 12 weeksHbA1c concentration
Change in interstitial glucose averageChange from 6 hours before (baseline) to 6 hours after (post-exercise) an exercise training sessionInterstitial average glucose measured via continuous glucose monitoring
Change in appendicular skeletal muscle massChange from baseline to 12 weeksMeasured by DEXA
Change in interstitial glucose time in hypoglycaemiaChange from 6 hours before (baseline) to 6 hours after (post-exercise) an exercise training sessionInterstitial glucose time in range (\<3.9mmol/L) measured via continuous glucose monitoring
Change in interstitial glucose time in hyperglycaemiaChange from 6 hours before (baseline) to 6 hours after (post-exercise) an exercise training sessionInterstitial glucose time in range (\>10mmol/L) measured via continuous glucose monitoring
Change in interstitial glucose variabilityChange from 6 hours before (baseline) to 6 hours after (post-exercise) an exercise training sessionInterstitial glucose variability measured via continuous glucose monitoring
Change in whole body fat massChange from baseline to 12 weeksMeasured by DEXA

Countries

Kuwait

Contacts

Primary ContactEbaa AlOzairi, MBChB
ebaa.alozairi@dasmaninstitute.rog+965 22242999

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026